...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Radiotherapy and oncology: Journal of the European Society for Therapeutic Radiology and Oncology >Tumour therapy with radionuclides: assessment of progress and problems.
【24h】

Tumour therapy with radionuclides: assessment of progress and problems.

机译：放射性核素的肿瘤治疗：进展和问题的评估。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Radionuclide therapy is a promising modality for treatment of tumours of haematopoietic origin while the success for treatment of solid tumours so far has been limited. The authors consider radionuclide therapy mainly as a method to eradicate disseminated tumour cells and small metastases while bulky tumours and large metastases have to be treated surgically or by external radiation therapy. The promising therapeutic results for haematological tumours give hope that radionuclide therapy will have a breakthrough also for treatment of disseminated cells from solid tumours. New knowledge related to this is continuously emerging since new molecular target structures are being characterised and the knowledge on pharmacokinetics and cellular processing of different types of targeting agents increases. There is also improved understanding of the factors of importance for the choice of appropriate radionuclides with respect to their decay properties and the therapeutic applications. Furthermore, new methods tomodify the uptake of radionuclides in tumour cells and normal tissues are emerging. However, we still need improvements regarding dosimetry and treatment planning as well as an increased knowledge about the tolerance doses for normal tissues and the radiobiological effects on tumour cells. This is especially important in targeted radionuclide therapy where the dose rates often are lower than 1Gy/h.
机译：放射性核素疗法是用于治疗造血源性肿瘤的一种有前途的方法，而到目前为止，治疗实体瘤的成功受到限制。作者认为放射性核素治疗主要是根除已扩散的肿瘤细胞和小转移瘤的方法，而大块的肿瘤和大转移瘤必须通过外科手术或外部放射疗法进行治疗。血液肿瘤的有希望的治疗结果使人们希望放射性核素疗法也将在治疗实体瘤中的弥散细胞方面取得突破。由于表征了新的分子靶结构并且关于不同类型的靶向剂的药代动力学和细胞加工的知识增加，与此相关的新知识不断涌现。关于它们的衰变特性和治疗应用，对于选择合适的放射性核素的重要因素也有了更好的理解。此外，正在出现改变肿瘤细胞和正常组织中放射性核素摄取的新方法。然而，我们仍然需要剂量学和治疗计划方面的改进，以及对正常组织的耐受剂量和对肿瘤细胞的放射生物学效应的更多了解。这在剂量率通常低于1Gy / h的靶向放射性核素治疗中尤其重要。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号